Handful Of Drugs Aim To Modify Osteoarthritis

Disease modifying treatments in Phase II target cartilage repair and regeneration. Sponsors are enthusiastic about FDA guidance offering to help sponsors with their programs.

PS1808_Osteoarthritiscovered_1030913119_1200.jpg

A new FDA draft guidance is casting a spotlight on a "Holy Grail" in drug development: disease-modifying treatments for osteoarthritis. While most osteoarthritis drugs in the pipeline are intended to treat pain and other symptoms, a handful seek to alter the underlying pathology and structural progression of the disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Pink Sheet